Using markers to improve pancreatic cancer screening and surveillance: a multi-center study

摘要 诊断为I期胰腺癌的患者比大多数人有更好的结果 患有晚期疾病的患者。胰腺癌筛查（CAPS）研究 目前跟踪了一个家族性/遗传性“高危”队列，约1500例患者接受常规胰腺炎治疗， 监视CAPS计划的最新结果表明，大多数维持常规治疗的患者 监测是向下分期，许多人被诊断为I期胰腺癌， 长期生存。循环肿瘤标志物检测目前不用于胰腺监测， 但我们建议对接受胰腺监测的患者进行血液检查。我们 将评估肿瘤标志物基因检测的使用，以更好地确定个人的肿瘤标志物正常 参考范围我们将评估使用等离子体磁共振波谱作为诊断测试， 利用人工智能方法来检测与以下疾病相关的微妙循环代谢变化： 得了胰腺癌我们还将确定血液生物标志物的变化是否发生在 诊断为胰腺癌。每年增加血液检查， 监测有望改善早期胰腺癌的检测。我们将继续 评估我们队列中患者的长期结局和未来的生物样本库 生物标记物研究。

Abstract Patients diagnosed with Stage I pancreatic cancer have a much better outcome than most patients who present with advanced disease. The Cancer of the Pancreas Screening (CAPS) study currently follows a familial/genetic “high-risk” cohort of ~1500 patients undergo regular pancreatic surveillance. Recent results from the CAPS program indicate that most patients who maintain regular surveillance are down-staged, many are diagnosed with Stage I pancreatic cancer and achieve long-term survival. Circulating tumor marker tests are not currently used for pancreas surveillance, but we propose to evaluate blood tests for patients undergoing pancreatic surveillance. We will evaluate the use of tumor marker gene tests to better define an individual’s tumor marker normal reference range. We will evaluate the use of plasma MR spectroscopy as a diagnostic test that utilizes artificial-intelligence methods to detect subtle circulating metabolic changes associated with having pancreatic cancer. We will also determine if blood biomarker changes occur before the diagnosis of pancreatic cancer in our cohort. The addition of annual blood tests to pancreatic surveillance is expected to improve the detection of early-stage pancreatic cancer. We will continue to evaluate the long-term outcomes of patients in our cohort and bank biospecimens for future biomarker studies.